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Background: Nearly 3 million people worldwide are coinfected with HIV and HCV.
Affordable strategies for prevention are needed. We developed a novel vaccination
regimen involving replication-defective and serologically distinct chimpanzee adenovirus
(ChAd3, ChAd63) vector priming followed by modified vaccinia Ankara (MVA) boosts, for
simultaneous delivery of HCV non-structural (NSmut) and HIV-1 conserved (HIVconsv)
region immunogens.
Methods: We conducted a phase I trial in which 33 healthy volunteers were sequentially
enrolled and vaccinated via the intramuscular route as follows: 9 received ChAd3-NSmut
[2.5× 1010 vp] and MVA-NSmut [2× 108 pfu] at weeks 0 and 8, respectively; 8 received
ChAdV63.HIVconsv [5 × 1010 vp] and MVA.HIVconsv [2 × 108 pfu] at the same interval;
16 were co-primed with ChAd3-NSmut [2.5 × 1010 vp] and ChAdV63.HIVconsv [5 ×
1010 vp] followed at week 8 by MVA-NSmut and MVA.HIVconsv [both 1 × 108 pfu].
Immunogenicity was assessed using peptide pools in ex vivo ELISpot and intracellular
cytokine assays. Vaccine-induced whole blood transcriptome changes were assessed
by microarray analysis.
Results: All vaccines were well tolerated and no vaccine-related serious adverse
events occurred. Co-administration of the prime-boost vaccine regimens induced high
magnitude and broad T cell responses that were similar to those observed following
immunization with either regimen alone. Median (interquartile range, IQR) peak responses
to NSmut were 3,480 (2,728–4,464) and 3,405 (2,307–7,804) spot-forming cells
(SFC)/106 PBMC for single and combined HCV vaccinations, respectively (p = 0.8).
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Median (IQR) peak responses to HIVconsv were 1,305 (1,095–4,967) and 1,005
(169–2,482) SFC/106 PBMC for single and combined HIV-1 vaccinations, respectively
(p = 0.5). Responses were maintained above baseline to 34 weeks post-vaccination.
Intracellular cytokine analysis indicated that the responding populations comprised
polyfunctional CD4+ and CD8+ T cells. Canonical pathway analysis showed that in the
single and combined vaccination groups, pathways associated with antiviral and innate
immune responses were enriched for upregulated interferon-stimulated genes 24 h after
priming and boosting vaccinations.
Conclusions: Serologically distinct adenoviral vectors encoding HCV and HIV-1
immunogens can be safely co-administered without reducing the immunogenicity of
either vaccine. This provides a novel strategy for targeting these viruses simultaneously
and for other pathogens that affect the same populations.
Clinical trial registration: https://clinicaltrials.gov, identifier: NCT02362217
Keywords: HIV-1, HCV (hepatitis C virus), vaccine, coadministration, clinical trial, conserved region, non-structural
protein (NS), transcriptomics analysis
INTRODUCTION
Hepatitis C virus (HCV) and human immunodeficiency virus
type 1 (HIV) are each responsible for significant global burden
of disease and premature death. Between 50 and 80% people
with acute HCV develop chronic infection and an estimated 71
million people are currently living with viraemic infection, which
is transmissible and carries the risk of long-term complications,
including fibrosis, cirrhosis and hepatocellular carcinoma (1,
2). Combinations of direct-acting antiviral agents now achieve
cure in >90% patients but their high cost is prohibitive in
both high and low resourced settings, with global treatment
coverage currently at only 13% (3, 4). Re-infection after successful
treatment is common in some populations (5).
Nearly 37 million people are living with HIV (PLWH), of
whom more than half are now accessing effective antiretroviral
therapy (ART). Scale up of access to ART and earlier initiation
of treatment have led to spectacular gains in life expectancy and
reductions in new infections, even in high prevalence regions (6).
However, therapy is life-long and does not provide a cure, placing
a considerable burden on patients and healthcare systems. Co-
infection with HCV and HIV affects 2.6 million people and
the incidence of HCV infection in HIV-positive men who have
sex with men is increasing (7–9). Progression to end-stage liver
disease (ESLD) is faster than in HCV mono-infection and ESLD
is now the leading cause of death in PLWH (10, 11).
Effective preventive vaccines would greatly strengthen the
current primary prevention strategies of “test-and-treat” and
pre- and post-exposure antiviral prophylaxis and would be cost-
effective for both HCV and HIV infections (12–14). Given
the overlapping epidemiology of HIV and HCV, strategies to
prevent co-infection are needed. However, significant obstacles
have hampered progress: a common feature of these viruses
is antigenic variability, which is driven by high rates of viral
replication and error-prone reverse transcription and which
enables frequent immune escape. The tissue tropism of HCV
and the persistence of latent reservoirs of replication-competent
HIV genomes each pose unique challenges for immune clearance.
Furthermore, the immune correlates of resolution of HCV and
long-term control of HIV are not fully defined.
Co-administration of vaccines against multiple pathogens
is fundamental to the success of childhood and adolescent
immunization programmes. As repeated doses are required
to achieve adequate immunity, many licensed vaccines are
administered as mixtures to ensure maximal population
coverage. The potential disadvantages are increased
reactogenicity and immune interference, with the latter
posing a risk of inadequate protection against one or more of the
targeted pathogens (15). However, several recent clinical trials
have shown no immune interference when vaccines for new
indications are co-administered with Expanded Programme on
Immunization vaccines, for example, tuberculosis (M72/AS01)
and malaria (chimpanzee adenovirus 63 and modified vaccinia
Ankara encoding multiple epitope string thrombospondin-
related adhesion protein) vaccine candidates, nor with
co-administration of rotavirus and measles-rubella vaccines
in infants and herpes zoster and influenza vaccines in adults
(16–19).
The development of vaccines for HCV and HIV has
focused on the induction of antibodies, preferably with broadly
neutralizing activity (bnAbs) and T cell responses (20, 21). bnAbs
are required for sterilizing immunity but have so far proved
difficult to elicit with conventional immunogens. CD4+ and
CD8+ T cells contribute to spontaneous clearance of HCV
and to long-term control of HIV (22–24). Non-human primate
studies have shown that live attenuated and replication-defective
viral vectors elicited the most potent virus-specific T cells in
the simian immunodeficiency virus (SIV) model; furthermore,
vaccine-induced T cells could abort infection at an early stage in
pathogenic challenge models of SIV and HCV (25–28). The main
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constraints on their use are safety and tolerability and complex
manufacturing requirements.
We have developed candidate vaccines for HCV and HIV
employing a potent heterologous viral vector platform for
antigen delivery. Priming with replication-defective chimpanzee
adenoviruses (ChAds) followed by boosting with modified
vaccinia Ankara (MVA) has proved to be highly efficient for
induction of T cells to a wide range of transgene products
in diverse populations and age groups (29, 30). We have
previously reported the safety and immunogenicity in human
volunteers of the novel immunogens, NSmut, comprising
the entire non-structural region from an HCV genotype
1b isolate, BK, and HIVconsv, comprising highly conserved
regions from HIV-1 clades A-D Gag, Pol, Vif, Env sequences
(Supplementary Figure 1), when delivered by ChAd and MVA
vectors (31–34). In the present study, we investigated the safety
and immunogenicity of these two vaccine strategies when co-




Healthy male and non-pregnant female volunteers aged 18–50
were invited to participate. All study visits and vaccinations were
performed at a single site in Oxford, UK.
Ethics and Regulatory Approval
This study was carried out in accordance with the
recommendations of UK National Research Ethics Service
(NRES Committee South Central—Oxford A 14/SC/0195) and
the UK Medicines and Healthcare Products Regulatory Agency
(Eudract no. 2014-000730-30). All subjects gave written informed
consent in accordance with the Declaration of Helsinki. The
protocol was approved by the NRES Committee South Central—
Oxford A. The study was registered with ClinicalTrials.gov
(NCT02362217) and conducted in accordance with ICH-GCP.
ICH-GCP compliance was independently monitored by the
University of Oxford Clinical Trials and Research Governance
office. A multinational independent data safety monitoring
committee (DSMC) provided safety oversight.
Study Design and Vaccinations
In this open-label study subjects were enrolled sequentially in
one of three groups. Group 1 (n = 9) received ChAd3-NSmut
(2.5 × 1010 vp) and MVA-NSmut (2 × 108 pfu) at weeks 0 and
8, respectively; Group 2 (n = 8) received ChAdV63.HIVconsv
(5 × 1010 vp) and MVA.HIVconsv l (2 × 108 pfu) at the same
interval, respectively). The dose of ChAd3-NSmut was based on
data from a previous trial which showed that transgene-specific
T cell responses reached a plateau at a higher dose of 7.5 ×
1010 vp (31). ChAdV63.HIVconsv has been previously tested at
two doses, 5 × 109 and 5 × 1010 vp; the latter was found to
be more immunogenic (33). Group 3 (n = 16) were co-primed
with ChAd3-NSmut (2.5 × 1010 vp) and ChAdV63.HIVconsv (5
× 1010 vp) at week 0 followed at week 8 by MVA-NSmut and
MVA.HIVconsv, each of which were given at half the dose (1
× 108 pfu) used in Groups 1 and 2 to maintain an equivalent
total dose of MVA (2× 108 pfu). Enrolment into Groups 2 and 3
commenced only after completion of priming immunizations in
the preceding groups.
Vaccines were manufactured in compliance with
Good Manufacturing Practice as described previously
(32, 33). Vaccine vials were stored at −80◦C until
use and thawed ≤30min prior to administration. All
vaccinations were administered intramuscularly into
the deltoid region of the arm. Group 3 subjects were
administered the HCV and HIV vaccines in separate
limbs.
Assessment of Primary Endpoints: Safety
and Reactogenicity
Volunteers were observed for up to 60min following
immunization. A safety review of the first three volunteers
in each group was conducted by the DSMC 48 h following each
vaccination, before proceeding to further vaccinations. Safety
evaluations comprised the following: (i) solicited symptoms
recorded by the participants on diary cards for 3 days following
each vaccination, (ii) unsolicited adverse events, (iii) physical
examination and (iv) monitoring of laboratory parameters, all of
which were recorded at follow-up visits on day 1, weeks 1, 2, 4,
8, 8 + 1 (day 57), 9, 12, 14, 34. Local and systemic events were
graded according to Grading Toxicity Tables given in the clinical
protocol (adapted from Division of AIDS 2004).
Ex vivo IFN-γ ELISpot Assay
IFN-γ ELISpot assays were performed with freshly isolated
peripheral blood mononuclear cells (PBMC) as described
previously, using an established laboratory SOP (31, 33). Peptide
sets (15-mers overlapping by 11 amino acids) corresponding
to the HCV NSmut immunogen (n = 494, BEI Resources)
and the HIVconsv immunogen (n = 166, Genscript) were each
tested in 6 pools (NSmut: ∼80 peptides/pool; HIVconsv ∼20–
30 peptides/pool). The final peptide concentration was 3µg/ml
(NSmut) or 2µg/ml (HIVconsv). PBMC were aliquoted at 2
× 105 cells/well for all time points; at week 9 both 1 × 105
and 2 × 105 cells/well were tested in order to ensure that the
anticipated peak response could be accurately quantified. The
assay cut-off was set at >48 SFC/106 PBMC for HCV NSmut
assays, as used previously (31); for HIVconsv assays, a cut-off of
>30 SFC/106 PBMC, based on the mean + 3 SD of all mock-
stimulated responses. Peptide-specific responses were defined as
positive only if they exceeded the assay cut-off and were at least
3-fold greater than the DMSO control value. The magnitude
of the response to each immunogen was obtained by summing
the DMSO-subtracted responses to each peptide pool that met
positivity criteria.
Intracellular Cytokine Assay
Intracellular cytokine secretion by antigen-specific T cell
was analyzed using multiparameter flow cytometry. Briefly,
cryopreserved PBMCs were thawed, washed and rested overnight
in R10 medium at 37◦C in a humidified incubator. Cells were
stimulated with HCV NSmut (1µg/ml), or HIVconsv peptide
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pools (2µg/ml), mock control (0.45% DMSO) and positive
controls (SEB, 5µg/ml; CMV pp65, 2µg/ml, NIH AIDS Reagent
Repository) at 37◦C for 6 h in the presence of Golgiplug,
Golgistop (BD Biosciences) and CD107a BV421. Following
viability and surface staining, cells were then fixed using
BD cytofix/cytoperm solution according to the manufacturer’s
instructions and intracellularly stained using reagents as listed
in Supplementary Table 1. At least 10,000 viable singlet CD3+
CD4+ or CD8+ lymphocyte events were acquired using a BD
Fortessa X20 cytometer. Data were analyzed using FlowJo v9.9.3
(FlowJo, US) and GraphPad Prism v7.0.
HLA Class I-Peptide Pentamer Staining
PE-labeled pentamers comprising HLA-A∗02:01-bound
HCV NS31406−1415 (KLSALGINAV) and HLA-A
∗01:01-
bound HCV NS31435−1443 (ATDALMTGY) were used to stain
HCVNSmut-specific CD8+T cells (Proimmune). The specificity
of pentamers was confirmed on HLA-matched pre-vaccination
samples from healthy individuals (31). Thawed PBMC (1–2
× 106) were coincubated with pentamers and antibodies
specific for cell surface or intracellular proteins, as listed in
Supplementary Table 2). Stained samples were fixed using 1%
paraformaldehyde and, where applicable, permeabilised using
10× permeabilisation buffer (eBioscience). Data were collected
with BD FACS DIVA software (San Jose, CA, USA) and analyzed
with Flow Jo software (Flowjo LLC, Ashland, OR, USA).
HLA Typing
HLA typing was performed by amplification refractory mutation
system (ARMS) PCR using sequence-specific primers.
Chimpanzee Adenovirus Neutralization
Assay
ChAd3 and ChAd63 neutralizing antibody (NAb) titres were
assayed as previously described using a secreted alkaline
phosphatase (SEAP) assay (35). Briefly, 8× 104 HEK293 cells per
well were seeded in a 96-well-plate for 1 day. SEAP-expressing
ChAds were pre-incubated for 1 h at 37◦C alone or with serial
dilutions of heat-inactivated serum from trial volunteers, added
to the 80–90% confluent HEK293 cells for 1 h at 37◦C, after
which the supernatant was replaced with 10% FBS in DMEM.
SEAP activity in the supernatant was measured after 24 ± 2 h
using the chemiluminescent substrate (CSPD) from Phospha-
Light kit (Tropix) following the manufacturer’s instructions.
Light signal output expressed as relative light units (RLU) was
measured 45min after the addition of the CSPD substrate using
a luminometer (Envision 2102 Multilabel reader, Perkin Elmer).
The neutralization titer was defined as the reciprocal of sera
dilution required to inhibit SEAP expression by 50% compared to
the SEAP expression of virus infection alone. The lowest dilution
tested was 1:18, therefore, a neutralization titer of<1:18 was used
as the negative cut-off.
RNA Isolation and Microarray
Blood samples for transcriptomic analysis of the innate
immune response were collected in Paxgene R© tubes at
weeks 0 (days 0 and 1), 7 and 8 (days 56 and 57). RNA was
isolated using the PAXgene Blood RNA kit (Qiagen) according
to the manufacturer’s protocol. Following globin depletion
(GLOBINclearTM Kit, ThermoFisher SCIENTIFIC) total
RNA was quantified using a NanoDrop spectrophotometer.
Transcription amplification and labeling (Illumina R©
TotalPrepTM-96 RNAAmplification Kit, Ambion) was performed
starting with 50 ng RNA per sample. After hybridization (Whole-
Genome Gene Expression Direct Hybridization, Illumina), the
slides were scanned on the Illumina iScan system (Wellcome
Trust Centre for Human Genetics, University of Oxford).
Host Transcriptome Analysis
The raw Illumina microarray probe data were annotated
into probe sets representing individual genes, using
readBeadSummaryData. Outliers were eliminated from the
data set and gene expression data were normalized using the
NEQC function (36). Two volunteers from Group 2 and one
volunteer from Group 3 were subsequently eliminated. The
array weight was calculated (Limma arrayWeight) to define the
minimal matrix to reflect the experimental settings (pre- and
post-vaccination time points). The probes that had p-value<0.05
in at least 10% of the samples were filtered. Gene expression
values (log2) at time points post-vaccination (day 1 and week
8 + 1 day) were converted to fold changes by subtracting the
respective pre-vaccination (days 0 and 56) expression values for
the same genes. Log2 expression values were tested for statistical
significance by ANOVA adjusted to false discovery rates using
the Benjamini–Hochberg False Discovery algorithm. Genes were
defined as differentially expressed post-vaccination if the fold
ratio was ≥1.5 and p-value ≤0.001. Gene networks and their
functional interactions were analyzed with Gene Ontology (GO)
enrichment analysis and visualization tool (http://cbl-gorilla.cs.
technion.ac.il/), STRING (https://string-db.org) and RStudio.
Group 1 samples were not analyzed for this study because a
similar analysis had been performed previously on 6 healthy
volunteers who had received the same vaccine regimen (ChA3-
NSmut 2.5 × 1010 vp on day 0 followed by MVA-NSmut (2 ×
108 pfu) on day 56 (week 8) and bleed schedule in the HCV003
trial (NCT01296451 (L. Swadling, personal communication).
Instead, we made a comparison of the data from Group 2 and
3 subjects with corresponding whole blood transcriptomic data
from the HCV003 subjects, as this had been generated using the
same methods.
Safety and Immunological Data Analysis
Safety and clinical laboratory data were entered on OpenClinica
software and checked by two staff members. For continuous
variables, the mean with standard deviation was used to
summarize hematological parameters; median with IQR were
used to summarize the immunogenicity data. Differences in
hematological parameters over time were tested for significance
by 1-way ANOVA. Differences between groups in the magnitude
and breadth of ELISpot responses over time were tested by
multiple t-tests with correction for multiple comparisons using
the Holm-Sidak method (alpha = 0.05). Other analyses were
performed using non-parametric tests. Statistical analysis of
safety and immunological data was performed using GraphPad
Prism version 7.
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RESULTS
Co-administration of Serologically Distant
Adenoviral Vectors Is Safe and
Well-Tolerated
Forty-eight subjects were screened for eligibility and 33 were
enrolled (19 females and 14 males). Vaccine allocation is
shown in Figure 1. Mean age at enrolment was 29 years
(range 19–48 years). One volunteer in Group 1 withdrew
consent after receiving the ChAd3-NSmut vaccination and was
replaced. All other volunteers completed the immunization
schedule. One volunteer in Group 3 withdrew consent after
receiving all vaccinations (week 12) but before completion
of follow-up (Participant flow chart, Figure 1). There
were no suspected unexpected serious adverse reactions
or serious adverse events. There were 301 solicited local
and systemic adverse events in total: 137 after priming
vaccinations and 164 after boosting vaccinations. Overall,
the majority of events related to vaccination were mild
(grade 1) in severity (178/301, 59%) and resolved within
48 h.
The most frequently reported solicited events were pain
at the injection site, myalgia, fatigue, headache and malaise.
ChAd-vectored vaccines were less reactogenic (38/137, 28%
grade 2 or3) than MVA vectored vaccines (85/164, 52% grade 2
or 3) (Figures 2A,B). ChAdV63.HIVconsv appeared to be more
reactogenic than ChAd3-NSmut, with four volunteers in Group
2 reporting at least one symptom of grade 2 or 3 compared with
only one in Group 1, possibly reflecting the different doses of
viral vector that were administered. Co-administration of the
two MVA-vectored vaccines at half the dose used in the single
regimen groups was as well-tolerated as vaccination with either
alone, likely reflecting the equivalent total dose of recombinant
MVAs across the three groups (Figures 2A,B).
The only abnormal laboratory parameter of note was
a transient fall in total lymphocyte count within 24 h of
administration of ChAd3-NSmut and ChAdV63.HIVconsv
vaccines. This became apparent in 24 volunteers after
implementation of a protocol amendment to perform a full
blood count estimation on day 1 post-vaccination as an
additional safety evaluation. Three episodes were classified
as grade 1 (0.8–0.91 × 109 cells/L), 11 were grade 2 (0.5–
0.8 × 109 cells/L), one was grade 3 (0.2–0.5 × 109 cells/L);
9 did not meet grading criteria. Mean (SD) counts (x109
cells/L) at day 0 and 1 were 1.99 (0.4) and 0.84 (0.3) for
volunteers who received a single vaccine regimen and 1.95
(0.5) and 0.94 (0.3) for volunteers given the combined vaccine
regimen (p < 0.0001 for both, Figure 2C). These changes were
not associated with any symptoms and lymphocyte counts
returned to normal by week 4 in all cases. Other hematological
parameters did not change significantly between days 0 and
1, except for a slight increase in monocyte counts (×109
cells/L) from a mean (SD) of 0.52 (0.2) to 0.7 (0.2) in the
combined vaccination arm (p = 0.01). Unsolicited adverse
events including abnormal laboratory parameters are listed in
Supplementary Tables 3, 4.
FIGURE 1 | Consort flow diagram showing enrolment and follow-up in the PEACHI 04 trial.
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FIGURE 2 | Frequency of local and systemic adverse events recorded by volunteers on diary cards. The proportion of volunteers reporting symptoms at any time
during 72 h following (A) ChAd- and (B) MVA-vectored vaccines is shown on the y axis. Color code indicates maximum severity of the reaction reported:
green—Grade 1 (mild); yellow—Grade 2 (moderate); red—Grade 3 (severe). (C) Peripheral blood lymphocyte counts were measured on day 1 in 23 subjects (two in
Group 1 and five in Group 2, shown as single ChAd prime; 16 in Group 3, combined ChAd primes). Respective lymphocyte counts on days 0 and 28 are shown for
comparison. By day 28, counts had returned to baseline values.
Magnitude and Breadth of Transgene
Product-Specific T Cell Responses
Induced by Combined Vaccine Regimens
Are Similar to Those of Each When Given
Alone
Ex vivo IFN-γ ELISpot assays were performed in all volunteers
at weeks 0, 1, 2, 4, 8, 9, 12, 14, and 34. One subject from each
of Groups 2 and 3 was excluded from the ELISpot analysis due
to mock-stimulated values exceeding the assay cut-off at three or
more time-points.
Peak responses to ChAd3-NSmut/MVA-NSmut were
observed at week 9 in 6/8 volunteers in Group 1 and 14/14
volunteers in Group 3. Median (IQR) responses at week 9 were
3,480 (2,728–4,464) and 3,405 (2,307–7,804) SFC/106 PBMC
for Groups 1 and 3, respectively (Figure 3A). Peak responses
to ChAdV63.HIVconsv/MVA.HIVconsv were detected at week
9 in 5/7 volunteers in Group 2 and 9/14 volunteers in Group
3. Median (IQR) responses at week 9 were 1,305 (1,095–4,967)
and 1,005 (169–2,482) SFC/106 PBMC for Groups 2 and 3,
respectively (Figure 3B). Responses at the final visit (week 34)
remained elevated above baseline in all groups (NSmut, Groups
1 and 3—p = 0.008 and 0.002, respectively; HIVconsv, Groups
2 and 3—p = 0.06 and 0.001, respectively, Wilcoxon matched
pairs test). Co-administration of HCV and HIV vaccines did
not have a significant impact on the magnitude of responses to
NSmut (Group 1 vs. Group 3) or HIVconsv (Group 2 vs. Group
3) at any time point (FDR, Q = 1%) (Figures 3A,B). Cumulative
responses in Group 3 (sum of NSmut- and HIVconsv-specific
T cells) exceeded responses to either immunogen alone after
boosting vaccinations (multiple t-tests: p = 0.008 and 0.0006
for NSmut and HIVconsv, respectively). Taken together, these
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FIGURE 3 | Frequency of antigen-specific T cells as determined by fresh ex vivo IFN-γ ELISpot assays. Mock-subtracted values are shown. Summed responses to
peptide pools spanning (A) NSmut in Group 1 (green) and Group 3 (blue) volunteers and (B) HIVconsv in Group 2 (purple) and Group 3 (light blue) volunteers. Black
horizontal bars indicate median values. (C) Cumulative responses (sum of NSmut and HIVconsv) in Group 3 subjects are compared with responses to the same
immunogens when administered as a single regimen. (D) Breadth (number of peptide pools eliciting a positive response) at the time of the peak response to priming
and boosting vaccinations. Group 3 (G3) values in right hand columns indicate the sum of HCV and HIV pools recognized. For (C,D), red bars indicate median values.
data indicate that there was no immune interference when
the vaccines were co-administered. Furthermore, all vaccinees
responded to transgene products at one or more time points
during follow-up (Figure 3C).
The minimum breadth of responses to each immunogen
was determined from the number of peptide pools that gave a
positive response, as defined in Materials and Methods. After
priming vaccinations, the median breadth was 4/6 NSmut pools
for both Groups 1 and 3, 6/6 HIVconsv pools for Groups 2 and
4/6 HIVconsv pools for Group 3. After boosting vaccinations,
the median breadth was 6/6 pools for all groups, with most
volunteers in Group 3 developing T cell responses to all 12
HCV and HIV peptide pools (Figure 3D). Cumulative breadth
in Group 3 (sum of NSmut and HIVconsv pools recognized)
also exceeded the breadth of responses in Groups 1 and 2 after
boosting vaccinations (multiple t-tests: p < 0.0001 for both),
confirming that co-administration of the HCV and HIV vaccines
in prime-boost regimens achieved similarly broad responses to
those observed after single vaccinations. It should be noted that
this may be a conservative estimate of the response breadth since
the response to any given pool may have been targeted to more
than one epitope.
Specificity and Immunodominance of
Vaccine-Induced T Cell Responses Is
Maintained When the HCV and HIV
Vaccines Are Co-administered
Analysis of the targets of vaccine-induced T cells showed that
responses to both immunogens were broad but were dominated
by HCV NS3 helicase (pool G) and HIV-1 Pol (pool 3), after
priming and boosting vaccinations with single regimens. These
immunodominance hierarchies were maintained when HCV
and HIV vaccines were co-administered, irrespective of whether
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the responses in Group 3 subjects were HCV-dominant (12/15
subjects) or HIV-dominant (3/15 subjects) (Figure 4). Although
responses were not mapped to individual peptides in this trial,
the immune response hierarchies were consistent with the genetic
background of the volunteers: HLA-A∗02 alleles were highly
represented in all groups (4/9 in Group 1, 5/8 in Group 2 and
10/16 in Group 3; several HLA-A∗02-restricted epitopes have
previously been identified in bothNS3 pool G andHIVconsv pool
3 (37, 38).
Induction of Multi-Functional
Antigen-Specific CD4+ and CD8+ T Cells
With Single and Combined Vaccine
Regimens
The functional capacity of antigen-specific CD4+ and CD8+
T cell populations was analyzed in all volunteers after
priming, boosting and at the end of the trial. The gating
strategy used to identify antigen-specific T cells is shown
in Supplementary Figure 2. As responses were dominated by
IFN-γ production, comparisons between single and combined
vaccine regimens in the frequencies of IFN-γ-producing cells
in each subset are shown (Figure 5). The median NSmut-
specific responses post-boost were similar for Groups 1
and 3 and were 0.15 and 0.12%, respectively for CD4+ T
cells and 0.15 and 0.26%, respectively for CD8+ T cells
(Figure 5; Supplementary Table 5). The median HIVconsv-
specific responses post-boost were also comparable for Groups 2
and 3 and were 0.035 and 0.04%, respectively for CD4+ T cells
and 0.06 and 0.06%, respectively for CD8+ T cells (Figure 5;
Supplementary Table 6). Overall, the frequencies of antigen-
specific responses detected by intracellular staining for IFN-γ
were lower than predicted by the ELISpot assay data, which may
reflect differences in the assay sensitivities (39).
These observations extended to the frequencies of other
cytokine-producing populations in the single and combined
vaccination groups (Supplementary Tables 5, 6). The dominant
antigen-specific marker expressed by CD8+ T cells after IFN-
γ was CD107a: median peak frequencies of NSmut-specific
cells in Groups 1 and 3 were 0.19 and 0.17%, respectively;
corresponding frequencies of HIVconsv-specific cells in Groups
2 and 3 were 0.07 and 0.02%, respectively. The dominant
signal in CD4+ T cells after IFN-γ was CD154 (CD40 ligand,
which is upregulated on activated CD4+ T cells), with median
peak frequencies of NSmut-specific cells in Groups 1 and 3 of
0.15 and 0.18%, respectively and of HIVconsv-specific cells in
Groups 2 and 3 of 0.06 and 0.05%, respectively. In all groups,
we detected transgene product-specific CD4+ T cells that co-
expressed IFN-γ, CD154, TNF-α and IL-2 and CD8+ T cells
that co-expressed IFN-γ, CD107a, and TNF-α (SPICE analysis,
Supplementary Figure 3).
The phenotype of NSmut-specific CD8+ T cells was
investigated further using HLA-A∗02:01- and HLA-A∗01:01-
peptide pentamers. Themedian frequencies of pentamer-positive
cells after ChAd3-NSmut priming were 0.014% and 0.49%
CD8+ T cells for Groups 1 and 3, respectively. These
increased to 3.78 and 4.4%, respectively after the MVA-
NSmut boost (week 9) and were still detectable at the end
of the trial (0.27 and 0.42%) (Supplementary Figures 4A,B).
Pentamer-positive populations were dominated by effector
memory T cells (TEM, CD45RA- CCR7-) that were
highly activated (CD38+/HLA-DR+) following prime
and boost vaccinations, whereas by the end of the trial,
a substantial proportion of these had been replaced by
terminally differentiated effectors (TEMRA, CD45RA
+ CCR7−)
(Supplementary Figure 4C). The vast majority of pentamer-
positive cells expressed granzymes A and B, apart from at
the end of trial, when frequencies of Granzyme A-positive
cells were significantly lower in Group 3 than Group 1
(Supplementary Figures 4D,E).
Collectively, these results indicate that the function and
phenotype of vaccine-induced HCV- and HIV-specific T cell
populations were maintained when the respective vaccines were
co-administered.
FIGURE 4 | Breadth and specificity of antigen-specific T cell responses as determined by ex vivo IFN-γ ELISpot assays: each bar shows the contribution of individual
peptide pools to the total response to the NSmut (red shades) and HIVconsv (blue shades) immunogens at the peak of the response after boosting vaccinations.
Although the peak response was most frequently observed at day 63, the day 84 or 98 response is shown for the few individuals with a later peak, to illustrate the
maximal breadth of individual responses. (A) Individual subjects are shown, indicated by trial identifier on x axis; (B) mean values per group.
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FIGURE 5 | Frequency of total antigen-specific IFN-γ+ cells within (left) CD4+
and (right) CD8+ T populations in volunteers in Groups 1 and 3 (NSmut
vaccines, top panels) and Groups 2 and 3 (HIVconsv vaccines, bottom panels)
after priming, boosting and at the end of trial (EOT) as determined by
intracellular cytokine staining of cryopreserved PBMC. Zero values were
arbitrarily assigned a value of 0.001 to enable display on a log10 scale.
Horizontal lines indicate median values. Groups were compared using
Kruskall-Wallis test; no statistically significant differences were found.
Adenovirus Type-Specific Neutralizing
Activities Were not Affected by Adenoviral
Vector Co-administration
ChAd-specific nAb titres were measured pre-vaccination and
at weeks 4 and 34 in all Group 1 and Group 2 subjects and
10/16 Group 3 subjects. At baseline, neutralizing activity against
ChAd3 and ChAd63 was detectable in 9/18 and 6/18 subjects,
respectively, although titres were <200 in the majority. An
increase in ChAd3 or ChAd63 titer of at least 4-fold was observed
in 8/18 Group 1 and 3 subjects and in 10/18 Group 2 and
3 subjects by week 4 (Figures 6A–D). Geometric mean values
for ChAd3-specific nAbs were 479 and 171 for Groups 1 and
3, respectively (p = 0.9). Geometric mean values for ChAd63-
specific nAbs were 298 and 234 for Groups 2 and 3, respectively
(p = 0.9). Although we could not discern a clear relationship
between baseline and post-vaccination neutralization titres due
to the small numbers of subjects analyzed these results suggest
that co-administration did not affect the nAb titer to the
reciprocal vector at peak or 8 months after priming.
We also investigated whether pre-existing ChAd-specific
humoral immunity impacted on priming of transgene-specific
T cell responses. No correlations between the baseline ChAd-
specific nAb titer and the magnitude of the respective T cell
response post-prime were observed (ChAd3 nAb vs. week 4
NSmut SFC/106 PBMC, r = 0.01, p = 1.0; ChAd63 nAb vs. week
4 HIVconsv SFC/106 PBMC, r = 0.05, p = 0.8) (Figures 6E,F),
suggesting that pre-existing nAbs at the titres observed here did
not significantly inhibit vector uptake into target cells.
Whole Blood Transcriptome Signatures
24h Post-vaccination Are Similar for Single
and Combined Vaccine Groups
Innate gene expression after vaccination has been shown to
determine functional adaptive immune responses, therefore, an
unbiased analysis of whole blood transcriptomes was undertaken
to investigate this (40–42). The global view of gene expression
analysis in total blood cells following each vaccine administration
showed that days 1 and 57 clustered together in both Groups
2 and 3 (Supplementary Figure 5). Comparison of the gene
expression profiles on day 1 with day 0 revealed that 1,773
and 1,633 genes were differentially expressed in Groups 2 and
3, respectively, of which 1,261 genes (59%) were common to
these groups (Figure 7A). Group 1 subjects were not analyzed
as subjects in the HCV003 trial received the same vaccination
regimen (see Methods; L. Swadling, personal communication)
and had already been subjected to the same transcriptional
analysis. This showed that 1,332 genes were differentially
expressed, of which 492 (19%) were shared with Group 3
(Figure 7A). Gene expression profiles were also substantially
affected by booster vaccinations, with differential expression of
1,450 and 2,307 genes in Groups 2 and 3, of which 1,155 (44%)
were shared between Groups 2 and 3. In HCV003 participants,
1,899 genes were differentially expressed after boosting, of which
949 (21%) were shared with Group 3 (Figure 7A). The number of
differentially expressed genes (DEGs) stratified by up- and down-
regulation after priming and boosting vaccinations is also shown
for Groups 2 and 3 as volcano plots (Figure 7B). Comparison
of Groups 2 and 3 showed that the proportions of both down-
and upregulated genes were similar after priming and also after
boosting.
Canonical pathway analysis was used to identify pathways
that are enriched within the set of DEGs that were significantly
upregulated. In the three vaccine groups the major pathways
included the antiviral response, IFN-I and IFN-II signaling
and response, regulation of IL-1-β secretion, inflammatory
responses, negative regulation of viral life cycle and regulation of
T-cell activation, after both priming and boosting vaccinations
(Figure 8A; Supplementary Table 7). However, some differences
were observed with each vaccine regimen: 24 h post-priming,
pathways such as neutrophil and leukocyte activation, TLR
signaling and regulation of IL-6 and IL-12 were only enriched in
ChAd63 (Group 2) and combined ChAd3/ChAd63 vaccine
recipients (Group 3), whereas the cytoplasmic pattern
recognition receptor signaling and regulation of IL-10 pathways
were only enriched in HCV003 vaccinees (Figure 8A). After
boosting vaccinations, this group also showed enrichment
of TRIF– and MyD88-dependent TLR signaling pathways
(Figure 8; Supplementary Table 7).
In view of the transient fall in peripheral blood lymphocyte
counts following administration of ChAd-vectored vaccines we
examined the association between lymphocyte count reduction
and DEGs. Groups 2 and 3 were combined since there
Frontiers in Immunology | www.frontiersin.org 9 January 2019 | Volume 9 | Article 3175
Hartnell et al. Vaccination Against HIV and HCV
FIGURE 6 | Neutralizing antibody titres to ChAd3 (A,B) and ChAd63 (D,E) measured in serum on day 0, week 4, and week 34 (end of trial) in volunteers receiving
single (left) and combined (middle) vaccination regimens. Horizontal dotted line indicates assay cut-off (titer of 18). Correlation analysis (Spearman) for pre-vaccination
vector-specific nAb titres and magnitude of the respective total transgene-specific T cell responses at W4 are shown in (C,F).
were no significant between-group differences in lymphocyte
counts pre- and post-vaccination (unpaired t-test for day 0—
p = 0.9; day 1—p = 0.5). This analysis revealed that a
total 289 of the upregulated genes were correlated with the
observed lymphopenia. Thirty-one of these genes were found
to be associated with regulation of locomotion (GO:0040012;
Figure 8B). Furthermore, 329 of downregulated genes were
correlated with lymphopenia post-ChAd vaccination. Many of
these are involved with biological functions other than the
immune response (e.g., initiation of RNA translation, elongation
and termination), while only 16 are associated with the immune
response, e.g., regulation of lymphocyte activation (data not
shown).
DISCUSSION
This trial has demonstrated that co-administration of vaccine
candidates comprising serologically distant simian adenoviruses
and MVA vectors that each encoded sequences from HCV
and HIV-1 was safe, well-tolerated and did not impair the
immunogenicity of either vaccine regimen.
The frequency and severity of local and systemic reactions
following dual immunizations with either ChAd- or MVA-
vectored vaccines were similar to those observed following
administration of each vaccine regimen alone. The higher
frequency of moderate or severe reactions after priming with
ChAdV63.HIVconsv, whether alone or in combination with
ChAd3-NSmut, could reflect the higher doses of the ChAd63
vector that were used (43, 44). The dose of each MVA vectored
vaccine, on the other hand, was halved for the co-administration
arm to avoid unacceptable reactogenicity. Overall, the safety
and tolerability profile of the four vaccines was similar to that
reported previously (32, 34).
As adenovirus-vectored vaccines targeting several globally
distributed pathogens advance to phase 2/3 trials in overlapping
populations, the possibility of anti-vector immunity and
antigenic competition, which may each adversely affect the
efficacy of existing immunization programmes and competing
vaccine candidates, is a legitimate concern. We have shown
that the magnitude, breadth, durability and quality of T
cell responses to the HCV and HIV immunogens were not
significantly affected by co-administration, and that responses
measured in this trial were similar to those reported in
previous trials in all these respects. There was, however,
a trend toward lower magnitude of HIVconsv-specific T
cell responses when given in combination with the HCV
vaccines. The optimal boosting dose of MVA.HIVconsv has
not been defined and we cannot exclude the possibility that
the lower dose of MVA.HIVconsv tested in Group 3 was
suboptimal.
We did not find evidence that transgene-specific T cell
responses were impacted by pre-existing anti-vector immunity
as the majority of study participants had ChAd-specific nAb
titres below the level of detection, possibly reflecting the age
of the study population (45, 46). However, vector-specific nAbs
were induced or boosted in the majority of vaccinees by week
4 and were maintained to week 34 at titres >200. Given that
adenovirus-specific nAbs were shown to dampen responses to
a heterologous Ad boost when these were administered after
a 20 week interval (31), our results support the notion that
administration of serologically related Ad in combination rather
than sequentially is a useful strategy to minimize the potential for
unwanted effects of anti-vector immunity.
This study enabled a direct comparison of responses to the
HCV and HIV vaccine regimens, which revealed differences in
the magnitude of induced T cell responses. NSmut-specific T
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FIGURE 7 | (A) Venn diagrams showing the proportion of genes that were significantly differentially expressed on days 1 and 57, i.e., 24 h post-prime and post-boost
vaccination, respectively, with data from the HCV003 trial participants (ChAd3-NSmut/MVA-NSmut, L. Swadling, personal communication) included for comparison
with Groups 2 and 3. (B) Volcano plots illustrate the numbers of the differentially expressed genes 24 h after vaccination. Red dots—genes significantly
downregulated; blue dots—significantly upregulated).
cell frequencies were generally of higher magnitude. Various
mechanisms may be implicated. ChAd3 was found to be more
potent than ChAd63 (and also rare human adenovirus serotypes)
for induction of SIV-specific CD8+ T cells in a mouse model,
therefore, it may be expected that differences in T cell priming
efficiency would be evident in humans (47). More plausibly,
the NSmut and HIVconsv immunogens differed considerably in
length (1,985 and 777 aa, respectively) and this is likely to be a
determinant of the number of potential T cell epitopes. Although
the breadth of induced T cell responses was not precisely defined,
the NS3-5 region of the HCV proteome is known to contain at
least 12 epitopes that are restricted by HLA-A∗02 alleles, which
were highly represented in the study population, along with
many more that are restricted by other class I and HLA class
II alleles, in particular, HLA-DR-restricted T cell epitopes that
are frequently recognized by people who spontaneously resolved
HCV infection (48–50). Furthermore, many of these epitopes
are immunodominant. The HIVconsv immunogen, on the other
hand, was specifically designed to minimize the targeting of
immunodominant regions, or “hotspots,” in which viral escape
frequently occurs, as was observed with native protein sequences
in Ad5-vectored vaccines (51, 52). Instead, the aim was to direct
responses to regions that are subdominant in natural infection.
A mapping study in healthy volunteers in the first HIVconsv
vaccine trial confirmed this: while responses to at least two
known HLA-A∗02-restricted Pol epitopes in 3/12 subjects were
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FIGURE 8 | (A) Canonical pathway analysis modulated by differentially expressed genes (DEGs) that were upregulated 24 h post each vaccine administration: left
panels—ChAd-vectored vaccines; right panels—MVA-vectored vaccines. The biological processes are depicted from DEGs in whole blood. The pathways are
indicated on the y axis, and the x axis shows the significance score (negative log10 of p-value calculated using Fisher exact test). (B) Heatmap depicting expression of
genes involved in locomotion (GO: 0040012), which are correlated with lymphocyte count decline on day 1. Groups 2 and 3 are shown separately but were pooled for
statistical analysis as the change in lymphocyte count was similar in the two groups.
observed, many new epitopes in HIVconsv were identified, yet
with a high degree of heterogeneity in responses across the study
population (38).
Multiparameter flow cytometric analysis indicated that
responses to both the NSmut and HIVconsv immunogens were
balanced with respect to the contribution of CD4+ and CD8+
T cells and that these comprised sub-populations expressing
combinations of IFN-γ, TNF-α, IL-2, CD107a, and CD154.
This was more evident in the HCV vaccine recipients due
to the higher magnitude of NSmut-specific T cell responses.
Nonetheless, the functional profiles observed in both HCV and
HIV vaccinees were similar in the single and combined vaccine
groups and were consistent with data from previous trials of
these vaccines (32, 33). The cytokine profile of CD4+ and
CD8+ T cells was reflective of a state of cleared or limited viral
antigen expression, which has been described in other healthy
vaccinated populations and inHIV controllers (32, 33, 50, 53, 54).
Furthermore, pentamer staining showed a similar kinetic of T
cell activation and expansion of NSmut-specific CD8+ T cells to
that described following administration of yellow fever, smallpox
and other recombinant MVA vaccines (55, 56). Interestingly,
although the majority of pentamer–positive populations induced
following prime and boost vaccinations were of a TEM phenotype,
these had had contracted by the end of the trial, as would
be expected in the context of vaccination or infection with
a non-persistent virus; however, a majority of these cells had
switched to a TEMRA phenotype with high levels of granzymes
being expressed. This is suggestive of ongoing antigen expression,
which has been reported previously in the context of replication-
deficient adenovirus vectors and was attributed to persistence of
transcriptionally active viral genomes at the site of immunization
and in secondary lymphoid organs (57, 58).
We observed transient lymphopenia 24 h post-administration
of ChAd-vectored vaccines, which was of similar severity in
those receiving single or combined vaccinations. This was
likely due to migration to secondary lymphoid tissues, as the
whole blood transcriptome showed significant up- and down-
regulation of genes involved in locomotion and regulation of
lymphocyte activation, respectively. Although we did not resolve
the lymphocyte subset changes, preliminary data indicate that a
reduction in absolute numbers of NK cells occurred during the
first 24 h (C. M. Gardiner, personal communication). Transient
lymphopenia has been reported previously in a clinical trial of
a ChAd63-vectored Leishmania vaccine; however, in this study
it was attributed to a predominant reduction in the frequency
of CD4+ T cells (59). We also observed that lymphopenia
was temporally associated with the upregulation of CCR2,
LYN, PAK1, PTK2B, SRC, STAT3, which are involved in the
chemokine signaling pathway. This may have accounted for
the concomitant increase in monocyte counts in the peripheral
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blood, which was more pronounced in Group 3 subjects. At
the same time, genes involved in inflammation and interferon
signaling were significantly upregulated, as has been reported
in other vaccine studies including those involving adenovirus-
vectored vaccines (42, 59). The observed changes were broadly
similar in Groups 2 and 3 and HCV003 (equivalent to Group
1), suggesting that dual administration of adenovirus vectors
did not amplify the effects of either alone. However, the
antigen processing and presentation via MHC class I pathway
was upregulated in Groups 2 and 3 and not in HCV003
subjects. Furthermore, many of the genes involved in the pattern
recognition receptor signaling pathway (e.g.,MYD88, CD36, CD
86, TANK, and TLR8), and in the T cell receptor signaling
pathway (HLA-DRA, HLA-DQB1, HLA-DRB3, HLA-DPA1, and
HLA-DB1) were not differentially expressed following ChAd3-
NSmut vaccination. These observations suggest that there are
some subtle differences in the ChAd3 andChAd63 vectors and/or
the design of the inserts that may impact on the quality of
immune responses to encoded antigens, although no substantial
differences in magnitude or functionality were evident from the
assays performed in this trial. The transcriptomic signatures
induced by the ChAd-vectored vaccines showed some overlap
with the effects of the MVA-vectored vaccines, with response to
virus, type I interferon signaling and cytokine-mediated signaling
pathways being highly represented in all groups. In addition,
profound upregulation of genes involved in leukocyte activation
and the inflammatory response was observed, in common with
previously described effects of otherMVA-vectored vaccines (60).
Limitations of this analysis were the use of whole blood, which
does not take into account variation in frequency of specific
cell populations. However, these data provide a foundation for
further dissection of heterogeneity in the host response to vaccine
candidates that may enable the identification of biomarkers of
efficacy.
In conclusion, we have demonstrated the feasibility of co-
administering two viral vector vaccine regimens to healthy
human subjects without undermining safety, tolerability or
induction of transgene product-specific T cell responses. Given
that there is an unmet need for effective vaccines not only
for control of established pandemics caused by HCV and HIV
but also for emerging and outbreak pathogens, combination
approaches will be crucial for ensuring maximal adherence and
population coverage and for minimizing the impact of anti-
vector immunity.
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